{"entity":{"id":"nct03865082","kind":"trial","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","aka":["ILLUMINATE-206"],"tldr":"A phase 2 trial of Nivolumab and Ipilimumab in advanced solid tumours, run by Idera Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) is a phase 2 interventional study registered as NCT03865082 by Idera Pharmaceuticals, Inc., with 30 participants enrolled, started 2019-10-29 and due to reach its primary completion in 2022-03. Interventions recorded: Tilsotolimod, Nivolumab and Ipilimumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03865082","url":"https://clinicaltrials.gov/study/NCT03865082"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":["idera-pharmaceuticals","bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03865082","phase":"2","setting":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors","sponsor":"Idera Pharmaceuticals, Inc.","participation":[{"nct":"NCT03865082","source":"https://clinicaltrials.gov/study/NCT03865082","fetchedAt":"2026-10-07T16:53:10.205Z","studySha256":"68439ed3368d8dce69c8053d82219d2ef9bc6d44549eb6f9b281fdb8a1ec0534","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2022-02-17","leadSponsor":"Idera Pharmaceuticals, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2019-10-29","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03865082/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/"}]}}